Objective: Placebo-controlled trials of antidepressants in patients with schizophrenia with prominent negative symptoms usually have presented contradictory results. Reboxetine is a norepinephrine reuptake inhibitor (NRI) antidepressant. Preceding studies regarding possible advantageous effects of reboxetine on deficit symptoms of schizophrenia, too, have resulted in inconsistent outcomes. The present study again assesses the effectiveness of reboxetine as an adjunctive treatment in a group of patients with schizophrenia with prominent negative symptoms.
INTRODUCTION
According to a number of studies, antidepressants do not have comparable and definite credentials as potential therapeutic agents for the management of negative symptoms 1 . Therefore, though negative symptoms (Affective Blunting, Alogia, Avolition, Apathy, Anhedonia, Asociality and Attention Deficit) are not uncommon in schizophrenia, their treatment is not an easy task. Moreover, in this regard other questions exist as well. For example, use of antidepressants in the presence of co-morbid depression in schizophrenia raises the issue that the treatment may be based mostly on an antidepressant effect, instead of direct impact on the negative symptoms. Most of the trials of antidepressants in schizophrenia are add-on studies, and placebo-controlled trials of antidepressants in non-depressed patients with schizophrenia have not demonstrated consistent results 2 . For example, while fluvoxamine 3 and escitalopram 4 showed more effectiveness than placebo in some assessments, there have been unsuccessful trials with citalopram and fluoxetine, too, making a reasoned conclusion more problematic 5 . Besides, while a double-blind trial with amitriptyline showed positive results 6 , no significant effect with maprotiline was visible in other studies 5 . Antidepressants like mirtazapine and mianserin have been studied with encouraging results 7 .
Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD; it is predominantly metabolized by the CYP3A4 isoenzyme. While it is structurally related to fluoxetine, it seems to be more effective than the latter for the treatment of persons with severe (melancholic) depression. Moreover, reboxetine may bring about rapid improvement in symptoms of social phobia. Social difficulties, too, like negative self-perception and a low level of social activity, appear to respond positively to reboxetine 8 . Reboxetine mainly acts as a pure norepinephrine reuptake inhibitor (NRI), with very little activity on the serotonin transporter and without direct effects on dopaminergic neurotransmission 9 , and hence is a relatively fine, selective "noradrenergic" agent. NRIs may be especially useful in drive-deficient, "anergic" states where lack of capacity for sustained motivation is evident, as is the case in the deficit syndrome of schizophrenia, and also in the treatment of retarded and melancholic depressive states with a reduced capability to deal with stress 8 . Previous studies by Raedler et al. 10 and Schutz et al.
11
regarding possible useful effects of reboxetine on negative symptoms of schizophrenia have presented contradictory results, so far, with a mixture of encouraging and futile outcomes. In the present trial, the effectiveness of reboxetine as an adjunctive drug has been assessed once more, in a group selected from a non-Western patient population of schizophrenic cases, to evaluate its usefulness for improvement of this cluster of debilitating symptoms.
METHODS
Fifty male inpatients meeting the diagnosis of schizophrenia according to the DSM-IV-TR were enrolled in a 12-week parallel group, double-blind study with random assignment to reboxetine (n=25 patients) or placebo (n=25 patients). Since the field of research was restricted to the male chronic psychosis unit of the psychiatric hospital, all the samples were selected among male chronic patients with schizophrenia. After complete explanation of the study to the subjects, written informed consent was obtained either from the participant or his legal guardian or representative. In addition, the entire procedure had been approved by the ethics committee of the university in September 2010. The inclusion criteria, in addition to the diagnosis of schizophrenia, involved the existence of obvious negative symptoms with a duration of at least two years. Cases with co-morbidities like major depressive disorder, mental retardation, neurological disorders, medical complications, severe aggressiveness, and medical deafness or muteness were excluded from the study. In addition, cases with a diagnosis of schizoaffective disorder or cases that were prescribed long-acting depot (during the last six months) or atypical antipsychotics, antidepressants or lithium were also excluded. The Scale for Assessment of Negative Symptoms (SANS) was used as the primary outcome measure in this trial to appraise affective blunting (restricted emotional expression), alogia (reduced spontaneous speaking), avolition (lack of drives), anhedonia (lack of sense of pleasure), and attention deficit. In addition, the Scale for Assessment of Positive Symptoms (SAPS), Simpson Angus Scale (SAS), Hamilton Rating Scale for Depression (HAM-D) and Mini-Mental Status Examination (MMSE) were used for comparison of the intervening parameters in this study. High negative symptom scores (more than 55% of total SANS, ≥66), low positive symptom scores (less than 55% of total SAPS, ≤96), and low extra-pyramidal symptom scores (less than 25% of total SAS, ≤10) were at the basis of our inclusion criteria. To exclude depression and cognitive disturbances that could be confused with negative symptoms, HAM-D and MMSE, respectively, were used. Therefore, HAM-D score of more than 10 and MMSE of less than 25 were identified as likely depression and cognitive disturbance and led to patient exclusion. All patients, after a waiting period of one week subsequent to the tapering off of their previous typical antipsychotics (neither group had received any form of depot injection during the last six months before entering the study), received haloperidol (5-20 mg/day). After a seven days' stabilization period, they were randomly assigned to the placebo or reboxetine (4 mg/day) group. Since higher doses of reboxetine, like other antidepressants, could increase the risk of intensification of psychosis, and the aim of the present assessment was evaluating the effectiveness of the drug merely on the negative symptoms of schizophrenia, a lower dosage was selected. In addition, atypical antipsychotics have been dismissed in the present trial on account of their possible amending influence on negative symptoms 12 . The prescribed tablets had been previously inserted into empty and similar capsules, specifically prepared to blind patients regarding the procedure. The evaluator (a psychiatrist), too, remained unaware regarding the abovementioned blinding procedure and the type of medications prescribed for each group. All of the patients remained hospitalized throughout the trial. Duration of the assessment was twelve weeks, and the patients were evaluated at baseline (week 0), and at the end of the 4 th , 8 th and 12 th week by SANS and SAPS.
Statistical Analysis
Patients were compared on baseline characteristics using chi-square test for categorical variables and t test for continuous variables. Treatment efficacy, too, was analyzed by t test and repeated-measures analysis of variance (ANOVA), comparing both groups over 12 weeks. Statistical significance was defined as a 2-sided p value ≤0.05. Cohen's Standard (d) and Correlation measures of effect size (r) were used for comparing baseline to endpoint changes in primary outcome measure. Response was defined as a reduction of 20% or more in the severity of SANS score (total and/or sub-scales). MedCalc Statistical Software version 15.2 was used as a tool for analysis.
RESULTS
Analysis for efficacy was based on data from an equal number of patients (n=25) in both groups. Since all of the patients were hospitalized during the study in the hospital and there were no serious adverse effects during the short duration of a s s e s s m e n t , t h e r e w a s n o p r e m a t u r e discontinuation either of the two groups; thus there was no dropout throughout the assessment. Groups were originally similar with respect to comparable demographic and diagnostic variables (Table 1 ). According to the findings and based on the changes of SANS, 76% of patients in the target group showed some positive response to reboxetine, in comparison with 24% in the control group ( χ 2 =5.76, df=1, p<0.01) (Table2 (Figure 1 ). Between-group analysis also showed that the mean total score of SANS in the reboxetine group, in comparison with the control group, improved significantly at 8 and 12 weeks (p<0.03 and p<0.01, respectively) ( (Figure 2 ). According to our findings, all of the subscales of SANS demonstrated significant improvement in the reboxetine group in comparison with the placebo group (Table2). Though during the present study no significant .83). 48% (n=12) of patients in the placebo group and 40% (n=10) of them in the reboxetine group required an anticholinergic drug for remission of tremor or Parkinsonism at some stage in the study ( χ 2 =0.081, df=1, p<0.77). Since the sample size was small, the effect size (ES) was analyzed for changes of SANS at the end of assessment, which showed a large (d≥0.8) improvement with reboxetine (Cohen's d=2.91, effect-size r=0.82). Post-hoc power analysis showed a power equal to 0.53 for this trial (intermediary), which turned to power=0.81 in compromise power analysis. Nine patients in the reboxetine group (36%) experienced some mild to moderate side effects such as headache, insomnia, constipation and dry mouth, but none of them led to any major problem or withdrawal from the trial.
DISCUSSION
"Negative symptoms are a significant barrier to successful functional outcome and recovery in individuals with schizophrenia" 13 . "Although the importance of studying negative symptoms may be clear, ideas regarding which aspects of psychopathology should be considered part of the negative symptom construct have changed over the years." "They also represent a primary unmet need in schizophrenia therapeutics, as no drug has received Food and Drug Administration (FDA) approval for an indication of negative symptoms" 14 . Objective of the present assessment included appraisal of possible usefulness of reboxetine, as adjunctive treatment, for deficit syndromes of schizophrenia, which include a whole collection of negative symptoms. Thus, according to the results, reboxetine caused a significant improvement in the negative symptoms, while on the other hand not causing an important increase in the positive symptoms. As is known, reboxetine is generally helpful in the treatment of major depressive disorder 1 . Moreover, it reduces olanzapineassociated weight-gain through activation of the adrenergic system 15 , an influence that is worthy of attention particularly in the course of treatment with atypical antipsychotics. Then again, perhaps dopamine-blocking properties of antipsychotic drugs have a negative effect, too, on mood and drive, and consequently, treatment with typical antipsychotics could be occasionally associated with emergence of depression in patients with schizophrenia 1 . Besides, there is some evidence that NRIs may enhance central serotonin function by a mechanism that is independent from reuptake inhibition. An association between negative symptoms and dysregulation of serotonin system is suggested by an abnormal prolactin response to fenfluramine in schizophrenia and schizoaffective disorder 1 . On the other hand, reboxetine also has a modulating effect on the dopaminergic cells in the ventral tegmental area and may cause a selective increase in dopamine availability in the prefrontal cortex. Thus it may potentially help to reverse a number of challenging side effects of antipsychotics on patients' mood and drive 15 . It should be mentioned at this point that, in a comparative study, reboxetine was considerably better than paroxetine and placebo regarding improvement of attention and enhancement of cognitive function in patients suffering from major depressive disorder 10 , an outcome that demands comparable studies with patients suffering from schizophrenia.
While in a six-week randomized controlled trial by Schutz and Berk with thirty patients with schizophrenia, there were no significant differences between reboxetine and placebo with regard to improvement of negative symptoms 11 , in an openlabel trial investigating the effectiveness and tolerability of adjunctive reboxetine in a group of patients with schizophrenia with prominent negative symptoms, all clinical scores improved significantly as a result of the augmentative treatments 10 . In addition, all of the patients tolerated the above-mentioned therapeutic maneuver without any major adverse effects. Therefore, the results of the present assessment were in agreement with the earlier study. Unfortunately, paucity of research in this regard prevents us from engaging in a more comprehensive debate, which once more highlights the necessity of conducting sufficiently powered, prospective, randomized placebo-controlled trials using potent end-result scales, concomitantly with functional outcome measures, to elucidate the efficacy of reboxetine as an adjunctive treatment for negative symptoms. Finally, it should not be overlooked that the short duration of the present assessment and minor dose of reboxetine may have prevented it from showing a better effectiveness. Besides, whether adding reboxetine to atypical antipsychotics could result in the same outcome or not needs another trial. Despite the fact that these results are investigative and need to be replicated by further analogous studies, they were encouraging because they have revealed significant amelioration of negative symptoms in a group of patients with schizophrenia.
Limitations of the Study
Small sample size and short duration of assessment were among the weak points of this trial. Also, gender-based sampling prevents us from generalization of the results to both genders.
